Eli Lilly price target raised to $1,260 from $1,145 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Eli Lilly (LLY) to $1,260 from $1,145 and keeps a Buy rating on the shares. Shares jumped 10% following strong earnings beats and 2026 guidance above consensus, reflecting 25% year over year growth and confidence in the obesity market despite accelerated pricing erosion, the analyst tells investors in a research note. Focus is expected to center on the upcoming 2Q26 launch of oral obesity pill orforglipron, with management noting minimal cannibalization of injectables and early validation of GLP-1 market expansion, Goldman adds.